OBJECTIVE: To test the hypotheses that some plasmin-reactive anticardiolipin antibodies (aCL) may bind to tissue plasminogen activator (tPA) and that some of the tPA-reactive aCL may inhibit tPA activity. METHODS: We studied the reactivity of 8 patient-derived monoclonal aCL with tPA and examined the presence of IgG anti-tPA antibodies in patients with the antiphospholipid syndrome (APS). The effects of the reactive monoclonal aCL on the activity of tPA were also examined. RESULTS: Six patient-derived plasmin-reactive monoclonal aCL bound to tPA. Analysis of plasma samples revealed that 10 of 80 APS patients (12.5%) and 1 of 81 systemic lupus erythematosus patients (1.2%) had antibodies against fibrin-associated tPA, based on a cutoff value equal to the mean + 2SD of the level in 28 normal subjects. Of the 6 tPA-reactive monoclonal aCL, 2 of them (CL1 and CL15) inhibited tPA activity. CONCLUSION: Some of the plasmin-reactive aCL in APS patients may bind to tPA. Of the tPA-reactive aCL, some (such as CL1 and CL15) may inhibit tPA activity and, thus, may be prothrombotic in the host.
OBJECTIVE: To test the hypotheses that some plasmin-reactive anticardiolipin antibodies (aCL) may bind to tissue plasminogen activator (tPA) and that some of the tPA-reactive aCL may inhibit tPA activity. METHODS: We studied the reactivity of 8 patient-derived monoclonal aCL with tPA and examined the presence of IgG anti-tPA antibodies in patients with the antiphospholipid syndrome (APS). The effects of the reactive monoclonal aCL on the activity of tPA were also examined. RESULTS: Six patient-derived plasmin-reactive monoclonal aCL bound to tPA. Analysis of plasma samples revealed that 10 of 80 APSpatients (12.5%) and 1 of 81 systemic lupus erythematosuspatients (1.2%) had antibodies against fibrin-associated tPA, based on a cutoff value equal to the mean + 2SD of the level in 28 normal subjects. Of the 6 tPA-reactive monoclonal aCL, 2 of them (CL1 and CL15) inhibited tPA activity. CONCLUSION: Some of the plasmin-reactive aCL in APSpatients may bind to tPA. Of the tPA-reactive aCL, some (such as CL1 and CL15) may inhibit tPA activity and, thus, may be prothrombotic in the host.
Authors: K K Hwang; J M Grossman; S Visvanathan; R U Chukwuocha; V L Woods; D T Le; B H Hahn; P P Chen Journal: J Immunol Date: 2001-12-15 Impact factor: 5.422
Authors: E M Tan; A S Cohen; J F Fries; A T Masi; D J McShane; N F Rothfield; J G Schaller; N Talal; R J Winchester Journal: Arthritis Rheum Date: 1982-11
Authors: Mesut Eren; Corrie A Painter; James B Atkinson; Paul J Declerck; Douglas E Vaughan Journal: Circulation Date: 2002-07-23 Impact factor: 29.690
Authors: Jacob H Rand; Xiao-Xuan Wu; Anthony S Quinn; Pojen P Chen; Keith R McCrae; Edwin G Bovill; Douglas J Taatjes Journal: Am J Pathol Date: 2003-09 Impact factor: 4.307
Authors: Annelies E Berden; Sarah L Nolan; Hannah L Morris; Rogier M Bertina; Dianhdra D Erasmus; E Christiaan Hagen; Donal P Hayes; Nico H van Tilburg; Jan A Bruijn; Caroline O S Savage; Ingeborg M Bajema; Peter Hewins Journal: J Am Soc Nephrol Date: 2010-09-16 Impact factor: 10.121